Increasing the clozapine: Norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy

Medical Hypotheses

Volumn 80, Issue 6, 2013, Pages 689-691

  Légaré, Nancy ^a   Grégoire, Claire Anne ^a   De Benedictis, Luigi ^a   Dumais, Alexandre ^a  

^a Institut Philippe Pinel de Montreal   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUVOXAMINE; NORCLOZAPINE;

ARTICLE; BODY WEIGHT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; METABOLIC DISORDER; NEUTROPENIA; SCHIZOPHRENIA; SIDE EFFECT;

CLOZAPINE; CYTOCHROME P-450 CYP1A2; DRUG COMBINATIONS; FLUVOXAMINE; HUMANS; SCHIZOPHRENIA;

EID: 84877104166     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.12.024     Document Type: Article

References (41)

1. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 5:789-796.
2. Lieberman J.A., Safferman A.Z., Pollack S., et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994, 151:1744-1752.
3. Chakos M., Lieberman J.A., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001, 158:518-526.
4. Atkinson J.M., Douglas-Hall P., Fischetti C., Sparshatt A., Taylor D.M. Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry 2007, 68:1027-1030.
5. Taylor D., Douglas-Hall P., Olofinjana B., Whiskey E., Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-lasting injection. Br J Psychiatry 2009, 194:165-167.
6. Pai N.B., Vella S.C. Reason for clozapine cessation. Acta Psychiatr Scand 2012, 125:39-44.
7. Khan A.Y., Preskorn S.H. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 2005, 11:289-301.
8. Szegedi A., Anghelscu I., Wiesner J., et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999, 32:148-153.
9. Deliliers G.L., Servida F., Lamorte G., Quirici N., Soligo D. In vitro effect of clozapine on hemopoietic progenitor cells. Haematologica 1998, 83:882-889.
10. Kuoppamaki M., Syvalahti E., Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993, 245:179-182.
11. Leucht S., Heres S., Kissling W., Davis J.M. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011, 14:269-284.
12. Lu M.L., Lane H.Y., Chang W.H. Differences between in vitro and in vivo determinations of fluvoxamine-clozapine interaction. J Clin Psychopharmacol 2001, 21:625-626.
13. Perry P.J., Miller D.D., Arndt S.V., Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenic patients. Am J Psychiatry 1991, 148:231-235.
14. Potkin S.G., Bera R., Gulasekaram B., et al. Plasma clozapine concentrations predict clinical response for treatment-resistant schizophrenia. J Clin Psychiatry 1994, 55(Suppl. B):133-136.
15. Kronig M.H., Munne R.A., Szymanski S., et al. Plasma clozapine levels and clinical response in treatment-refractory schizophrenic patients. Am J Psychiatry 1995, 152:179-182.
16. Lu H.C., Chang W.H., Wei F.C., Lin S.K., Jann M.W. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996, 18:200-207.
17. Ulrich S., Baumann B., Wolf R., et al. Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003, 41:3-13.
18. Linnet K., Olesen O.V. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997, 25:1379-1382.
19. Sporn A.L., Vermani A., Greenstein D.K., et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007, 46:1349-1356.
20. Lee S.T., Ryu S., Nam H.J., Lee S.Y., Hong K.S. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Int Clin Psychopharmacol 2009, 24:139-144.
21. Couchman L., Morgan P.E., Spencer E.P., Flanagan R.J. Plasma clozapine, norclozapine, and the clozapine: norclozapine ratio in relation to prescribed dose and other factors:data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010, 32:438-447.
22. Szegedi A., Wiesner J., Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995, 15:141-142.
23. Lu M.L., Lane H.Y., Chen K.P., Jann M.W., Su M.H., Chang W.H. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000, 61:594-599.
24. Papetti F., Morel-Pingault V., Buisse V., et al. Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports. Encephale 2007, 33:811-818.
25. Lu M.L., Lane H.Y., Lin S.K., Chen K.P., Chang W.H. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004, 65:766-771.
26. Lammers C.H., Deuschle M., Weigmann H., et al. Coadministration of clozapine and fluvoxamine in psychotic patients: clinical experience. Pharmacopsychiatry 1999, 32:76-77.
27. Hinze-Selch D., Deuschle M., Weber B., Heuser I., Pollmacher T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 2000, 149:163-169.
28. Weiner D.M., Meltzer H.Y., Veinbergs I., et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 2004, 177:207-216.
29. Zhou S.F., Wang B., Yang L.P., Liu J.P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010, 42:268-354.
30. Chang W.H., Augustin B., Lane H.Y., et al. In vitro and in vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) 1999, 145:91-98.
31. Koponen H.J., Leinonen E., Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996, 6:69-71.
32. Hiemke C., Weigmann H., Hartter S., Dahmen N., Wetzel H., Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994, 14:279-281.
33. Armstrong S.C., Stephans J.R. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. J Clin Psychiatry 1997, 58:499.
34. Lu M.L., Lane H.Y. Adjunctive fluvoxamine with clozapine. Br J Psychiatry 2003, 182:81.
35. Kuo F.J., Lane H.Y., Chang W.H. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 1998, 18:483-484.
36. Chong S.A., Tan C.H., Lee H.S. Worsening of psychosis with clozapine and selective serotonin inhibitor combination: two case reports. J Clin Psychopharmacol 1997, 17:68-69.
37. Peritogiannis V., Tsouli S., Pappas D., Mavreas V. Acute effects of clozapine-fluvoxamine combination. Schizophr Res 2005, 79:345-346.
38. Lameh J., Burstein E.S., Taylor E., Weiner D.M., Vanover K.E., Bonhaus D.W. Pharmacology of N-desmethylclozapine. Pharmacol Ther 2007, 115:223-231.
39. Barnes T.R. Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011, 25:567-620.
40. Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B. Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010, 36:94-103.
41. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005;50(Suppl. 1):7S-57S.